Clarius Group LLC upped its Regeneron stake by 82.1% last quarter, gobbling up 509 extra shares like they were on clearance.

The 12-month price targets, analyzed by analysts, offer insights with an average target of $33.11, a high estimate of $68.00, ...

Regeneron Pharmaceuticals REGN has outperformed the market over the past 20 years by 14.22% on an annualized basis producing an average annual return of 22.54%. Currently, Regeneron Pharmaceuticals ...

Regeneron Pharmaceuticals has declined to submit a new bid for genetic testing company 23andMe exceeding its original winning ...

This was the stock's second consecutive day of losses.

The stock's fall snapped a two-day winning streak.

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) received a ‘Hold’ rating from Wells Fargo, which set the company’s stock price ...

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company’s products include EYLEA injection ...

Anne Wojcicki is taking back reins of 23andMe after outbidding Regeneron. The entrepreneur's proposal offers better ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Factory Mutual Insurance Co. dramatically upped its stake in Regeneron Pharmaceuticals by 210.3%, acquiring an additional ...